Arcutis Biotherapeutics Inc (ARQT)
9.43
+0.17
(+1.84%)
USD |
NASDAQ |
Nov 18, 16:00
9.53
+0.10
(+1.06%)
Pre-Market: 08:34
Arcutis Biotherapeutics Revenue (Quarterly): 44.76M for Sept. 30, 2024
Revenue (Quarterly) Chart
Historical Revenue (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2024 | 44.76M |
| June 30, 2024 | 30.86M |
| March 31, 2024 | 49.57M |
| December 31, 2023 | 13.53M |
| September 30, 2023 | 38.11M |
| Date | Value |
|---|---|
| June 30, 2023 | 5.19M |
| March 31, 2023 | 2.781M |
| December 31, 2022 | 2.961M |
| September 30, 2022 | 0.725M |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (Quarterly) Range, Past 5 Years
0.725M
Minimum
Sep 2022
49.57M
Maximum
Mar 2024
20.94M
Average
13.53M
Median
Dec 2023
Revenue (Quarterly) Benchmarks
| Mirum Pharmaceuticals Inc | 90.38M |
| Biogen Inc | 2.466B |
| Vertex Pharmaceuticals Inc | 2.772B |
| NovaBay Pharmaceuticals Inc | 2.441M |
| Palatin Technologies Inc | -- |
Revenue (Quarterly) Related Metrics
| Net Income (Quarterly) | -41.54M |
| Total Expenses (Quarterly) | 83.82M |
| EPS Diluted (Quarterly) | -0.33 |
| Enterprise Value | 977.78M |
| Gross Profit Margin (Quarterly) | 87.70% |
| Profit Margin (Quarterly) | -92.81% |
| Earnings Yield | -18.98% |
| Normalized Earnings Yield | -18.98 |